NeoGenomics, Inc. (NEO) Stock Forecast
NEO analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 12 analysts
- Price target
- $21.85 average of analyst targets
- Upside to target
- +31.2% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $-0.01
- 52-week range
- $7.19 – $19.91
NEO analyst ratings
12 analystsNumber of analysts at each rating.
NEO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NEO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.06 | $0.04 | $0.07 | $0.03 | +84.8% | 11 |
| Current fiscal year (2026) | $0.19 | $0.16 | $0.20 | $0.12 | +56.1% | 11 |
| Next fiscal year (2027) | $0.34 | $0.27 | $0.41 | $0.19 | +83.0% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NEO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $207.3M | $205.8M | $209.3M | +10.4% | 10 |
| Current fiscal year (2026) | $805.2M | $799.5M | $808.5M | +10.7% | 12 |
| Next fiscal year (2027) | $885.4M | $874.7M | $903.0M | +10.0% | 12 |
NEO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NEO revenue: reported and forecast
NEO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.06 | $0.05 | $0.05 | $0.05 | $0.06 | −0.9% | 2 up · 1 down |
| Current fiscal year (2026) | $0.18 | $0.18 | $0.18 | $0.18 | $0.19 | +2.3% | 3 up · 0 down |
| Next fiscal year (2027) | $0.36 | $0.34 | $0.34 | $0.34 | $0.34 | −6.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NEO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NEO beat in 9 of 12.
What analysts expect from NEO
12 analysts cover NeoGenomics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.85, 31.2% above the latest close of $16.65. Analysts expect earnings of $0.19 per share for 2026, +56.1% from a year earlier. For 2027 the average estimate is $0.34 per share on revenue of $885.4 million. NeoGenomics beat the EPS estimate in 9 of the last 12 quarters.
Related: NEO income statement, NEO key metrics, NEO chart. See the NEO stock overview for the latest quote and news.
NEO forecast FAQ
What is NeoGenomics's price target?
The average analyst price target for NeoGenomics is $21.85, 31.2% above the latest close of $16.65.
Is NeoGenomics a buy, hold or sell?
Of 12 analysts covering NeoGenomics, 7 rate it a strong buy, 2 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NeoGenomics's EPS forecast?
Analysts forecast $0.19 per share for 2026 (range $0.16 to $0.20); for 2027 the estimate is $0.34.
What is NeoGenomics's revenue forecast?
The average revenue estimate for 2026 is $805.2 million, growth of 10.7%; for 2027 it is $885.4 million.
When does NeoGenomics report earnings?
NeoGenomics is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes; the EPS estimate is $-0.01.
Does NeoGenomics usually beat earnings estimates?
NeoGenomics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.